(Q33406190)

English

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study (English)

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

9

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Jorge Eduardo Cortes

1

object named as

Jorge Cortes

1 reference

Europe PubMed Central

30 September 2017

PMC publication ID

4

object named as

David Rizzieri

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Anjali S Advani

5

object named as

Anjali S Advani

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

author name string

Eric Feldman

2

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Karen Yee

3

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Anthony Charman

6

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Richard Spruyt

7

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Martin Toal

8

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

publication date

28 February 2013

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

14

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

4

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

354-362

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

21 June 2018

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

21 June 2018

A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

21 June 2018

CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

21 June 2018

Age and acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

21 June 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

21 June 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

21 June 2018

Trends in the treatment of acute myeloid leukaemia in the elderly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

31 October 2018

Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

31 October 2018

Amino acid limitation regulates CHOP expression through a specific pathway independent of the unfolded protein response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557006

31 October 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970037-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70037-8

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33406190&oldid=1857947853"